Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Long-acting veterinary polypeptides and methods of producing and administering same

a polypeptide, long-acting technology, applied in the field of polypeptides and polynucleotides encoding same, can solve the problems of preventing the development of many otherwise promising drug candidates, affecting the clinical value of the drug, so as to improve the biological half life

Inactive Publication Date: 2007-08-09
MODIGENE INC
View PDF33 Cites 65 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0015] In another embodiment, the present invention provides a method of treating or reducing the incidence associated with a growth, weight-related, or metabolic condition in a non-human subject, comprising administering to a subject a therapeutically effective amount of CTP-GH, thereby treating a non-human subject having a growth, weight-related, or metabolic condition. In another embodiment, the GH peptide is a non-human GH peptide. In another embodiment, the GH peptide is a human peptide. Each possibility represents a separate embodiment of the present invention.
[0016] In another embodiment, the present invention provides a method of improving a biological half life of a non-human peptide of interest, comprising the step of attaching at least two chorionic gonadotrophin CTP sequences to the non-human peptide of interest, thereby improving a biological half life of a non-human peptide of interest.

Problems solved by technology

Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney.
Moreover, since peptide drugs are usually administrated by infusion, frequent injection of peptide drugs cause considerable discomfort to a subject.
Unfavorable pharmacokinetics, such as a short serum half-life, can prevent the pharmaceutical development of many otherwise promising drug candidates.
For example, with lower molecular weight polypeptide drugs, physiological clearance mechanisms such as renal filtration can make the maintenance of therapeutic levels of a drug unfeasible because of cost or frequency of the required dosing regimen.
Conversely, a long serum half-life is undesirable where a drug or its metabolites have toxic side effects.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Long-acting veterinary polypeptides and methods of producing and administering same
  • Long-acting veterinary polypeptides and methods of producing and administering same
  • Long-acting veterinary polypeptides and methods of producing and administering same

Examples

Experimental program
Comparison scheme
Effect test

example 1

Generation of EPO Constructs

Materials and Methods:

[0278] Construction of expression vector pCI-dhfr: pCI-neo mammalian expression vector was purchased from Promega (catalog no. E1841). The vector contains a CMV IE enhancer / promoter and neomycin phosphotransferase gene. The pSV2-dhfr clone was purchased from ATCC (Catalog No. 37146). The plasmid contains the murine dhfr gene. The construction of pCI-dhfr vector was performed as follows: [0279] a. The pSV2-dhfr plasmid was digested with restriction enzyme BglII (3′ end of the dhfr gene). DNA polymerase I, Large (Klenow) Fragment was used to fill-in the 5′ overhangs to form blunt ends. The DNA was then digested with restriction enzyme AvrII (5′ end of the dhfr gene). The dhfr gene (AvrII-blunt end) fragment was isolated. [0280] b. The pCI-neo vector was digested with restriction enzyme BstXI (3′ end of the neo gene). DNA polymerase I, Large (Klenow) Fragment was used to remove the 3′ overhangs to form blunt ends. The DNA was then di...

example 2

Expression and Isolation of EPO-CTP Polypeptides

Materials and Methods

[0298] DNA transfection and clone selection: DG44 cells were transfected with pCI-DHFR expression vectors containing EPO-CTP variants using FuGENE6 Reagent (FUGENE Transfection Reagent—Roche Cat. 11 815 091 001). 48 hr following transfection, cells were diluted and seeded at 50-200 cells per well in a selective medium (CD DG44 Medium w / o HT (Gibco: Scotland part: #07990111A) Sku num.: ME060027 supplemented with 8 mM L-Glutamine Biological Industries: Cat: 03-020-1A) and 18 mL / L of 10% Pluronic F-68 solution (Gibco: Cat: 240040-032). Selected clones were screened for highest protein production using commercial ELISA. 3-5 producing clones per each variant were frozen for a backup cell bank. A selected clone for each variant was adapted to growth in larger scale cultures up to 1 L flasks on an orbital shaker platform. Supernatants were collected and analyzed by ELISA, SDS-PAGE and western blot. Following the withdr...

example 3

Biological Activity of the EPO-CTP Polypeptides of the Present Invention

[0304] The TF-1 bioactivity test represents the ability of the EPO-CTP variants to bind its receptor and then stimulate activity which results in cell proliferation. Therefore, this test was used as a first step in evaluating the biological potency of the EPO-CTP polypeptides of the present invention.

Materials and Methods

[0305] Cell Proliferation Analysis: Proliferation assay was performed with the cell line TF-1, measuring levels of MTT cellular stain as a function of EPO activity (Kitamura et al., Kitamura, T. et al. (1989) Establishment and characterization of a unique human cell line that proliferates; Hammerling U. et al. In vitro bioassay for human erythropoietin based on proliferative stimulation of an erythroid cell line and analysis of carbohydrate-dependent microheterogeneity. Journal of Pharm. Biomed. Analysis 14(11): 1455-1469 (1996). Exponentially growing TF-1 cells were washed twice, plated at ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Volumeaaaaaaaaaa
Login to View More

Abstract

A polypeptide and polynucleotides comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a non-human peptide-of-interest are disclosed. Pharmaceutical compositions comprising the non-human polypeptides and polynucleotides of the invention and methods of using both human and non-human polypeptides and polynucleotides are also disclosed.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application claims priority of U.S. Provisional Application Ser. No. 60 / 764,761, filed Feb. 3, 2006, which is hereby incorporated in its entirety by reference herein.FIELD OF INVENTION [0002] A polypeptide and polynucleotides encoding same comprising at least two carboxy-terminal peptides (CTP) of chorionic gonadotrophin attached to a peptide-of-interest are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed. BACKGROUND OF THE INVENTION [0003] Polypeptides are susceptible to denaturation or enzymatic degradation in the blood, liver or kidney. Accordingly, polypeptides typically have short circulatory half-lives of several hours. Because of their low stability, peptide drugs are usually delivered in a sustained frequency so as to maintain an effective plasma concentration of the active peptide. Moreover, since peptide drugs are usually a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12P21/06C07H21/04C07K14/59C07K14/51
CPCC07K14/505C07K14/555C07K14/59A61K38/00C07K2319/00C07K2319/31C07K14/61A61P3/00A61P3/04A61P31/12A61P35/00A61P43/00A61P5/06A61P7/00A61P7/06A61K38/19A61K38/24C07K14/52C07K14/575C07K19/00A61K38/1816A61K38/20A61K38/27
Inventor FARES, FUADFIMA, UDI EYAL
Owner MODIGENE INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com